Health Care · Services-Medical Laboratories

CDNA CareDx, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1217234134 filings
Russell 2000

CDNA at a glance

CareDx, Inc. (CDNA, SEC CIK 1217234) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CareDx, Inc. (CDNA) reported revenue of $379.8 million (up 13.8% from FY2024) and a net loss of $21.4 million. Diluted EPS was -$0.40.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding CareDx, Inc. (CDNA) shares worth $1.5 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Riggsbee Richard Bryan on November 16, 2026 of 800 shares at $75.95 per share.
  • In the last 90 days, CDNA insiders reported 0 open-market purchases ($0) and 20 open-market sales ($6.8M) on Form 4, a net sale of $6.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$379.8M
+13.8% vs prior year
Insiders · 90 days
0 buys · 20 sells
Net −$6.8M
13F holders
30 funds
$1.5B · −1 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 7.01 · Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Specialized molecular diagnostic testing and digital pharmacy solutions for transplant patients
  • Expanded patient and digital solutions revenue by 31%, driven by pharmacy sales growth and wider Ottr software deployment
  • Strategic share repurchase programs totaling $88 million in 2025, reflecting confidence despite net loss of $21 million
  • Testing services volume increased 14% to approximately 200,000 tests, with overall revenue growth of 14% to $380 million
  • Noteworthy litigation expense reversal in 2024 due to favorable patent ruling, partially offset by 2025 Securities Class Action settlement

Risk Factors

  • MolDX/Noridian Proposed LCD revision may reduce reimbursement, impose utilization limits, and introduces bundled payment, with final decision due within 365 days from July 17, 2025
  • Medicare reimbursement risk: 46% of testing revenue from Medicare, with AlloSure Kidney 2026 fee reduced by $88 to $2,753 per test after CMS crosswalk decision
  • Dependency on single California lab facility; if inoperable, inability to perform core tests AlloSure Kidney, AlloMap Heart, HeartCare, and AlloSure Lung
  • Competitive risk from rapid technological evolution in transplantation diagnostics, could render CareDx’s AlloSure and AlloMap tests obsolete
  • Concentration risk around Medicare Advantage payer dispute over denied and recouped claims, creating financial uncertainty and potential repayment obligations

Management Discussion & Analysis

  • Revenue recognition includes testing services, product sales, patient and digital solutions; testing revenue reduced by $3.5M refund reserve in 2025
  • No profitability or margin figures disclosed in the provided text
  • Management sees no goodwill or intangible asset impairments as of Dec 31, 2025; foreign operations risks noted but no quantified impact or guidance

AI summary of the CDNA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $139.4M, up 39% YoY from $100.1M
  • Testing Services best performer: $119.2M, up 65% YoY; Product revenue worst, $0 vs $12.5M
  • Operating margin 5.8% vs (0.2)% YoY; net income $19.3M vs $1.7M
  • Operating cash flow $13M; nine-month cash $250.5M, with $164.8M sale proceeds and $145.8M Naveris acquisition
  • NavDx outlook sensitive to payer coverage, clinician adoption, competition and Naveris integration; up to $100.0M contingent consideration tied to 2026 and 2027 revenue milestones

Risk Factors

  • Newly emphasized AI risk: healthcare AI may produce inaccurate or biased outputs, triggering regulatory scrutiny, product complaints, recalls, or liability claims
  • Medicare reimbursement risk: 2027 preliminary rates show AlloSure rising from $2,753 to $2,840, but final CMS rates remain subject to revision
  • Regulatory compliance risk: FDA LDT oversight remains uncertain after 2025 rule reversal, potentially requiring additional studies and PMA or 510(k) submissions
  • Competitive risk: NavDx faces larger ctDNA competitors with broader oncology menus, stronger payer relationships, and greater resources
  • Financial risk: cash and equivalents totaled $250.5 million against a $486.2 million accumulated deficit, with additional capital potentially required

AI summary of the CDNA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation current as of September 30, 2026
  • Investor materials available on CareDx’s website

Item EX-99.1: Item EX-99.1

  • Q3 revenue $139.4M, up 39% YoY, led by Testing Services growth of 65% to $119.2M
  • GAAP net income $19.3M, margin 14%, versus $1.7M and 2% in Q3 2025

Item 2.02: Results of Operations and Financial Condition

  • CareDx announced financial results for the quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed quarterly results and management commentary
Filed Sep 16, 2026Full analysis →

Item 2.01: Completion of Acquisition or Disposition of Assets

  • CareDx completed its acquisition of Naveris, expanding its portfolio through the acquired Delaware-based company
  • Amendment adds Naveris historical financial statements and Article 11 pro forma information
Filed Jul 30, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation current as of June 30, 2026
  • Investor-relevant business information available on CareDx’s website

Item 2.02: Results of Operations and Financial Condition

  • CareDx announced financial results for the quarter ended June 30, 2026
  • Full results and management commentary appear in Exhibit 99.1, the accompanying press release

Item EX-99.1: Item EX-99.1

  • Q2 revenue $132M, up 52% YoY, with Testing Services revenue up 61% to $100M
  • Adjusted EBITDA $25M, up from $5M, with margin reaching 19% from 6%

AI summaries of CDNA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CDNA

Don't miss the next CDNA filing

  • Alerts as it files. A push when CDNA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CDNA, by share count.
  • Ask anything. An AI agent that reads every CDNA filing and answers with sources.

CDNA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Riggsbee Richard BryanSellNov 16, 2026$75.95
Riggsbee Richard BryanSellNov 16, 2026$74.74
Riggsbee Richard BryanSellNov 16, 2026$77.02
Riggsbee Richard BryanSellNov 16, 2026$74.02
Kennedy KeithMNov 12, 2026$29.43
Kennedy KeithSellNov 12, 2026$78.78
Kennedy KeithSellNov 12, 2026$79.61
Goldberg MichaelSellNov 12, 2026$79.85

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$280.3M$333.8M$379.8M
Operating Income-$203.4M$40.8M-$30.8M
Net Income-$190.3M$52.5M-$21.4M
Op. Margin-72.5%12.2%-8.1%
Net Margin-67.9%15.7%-5.6%
Balance Sheet
Total Assets$466.8M$491.1M$413.2M
Equity$261.3M$378.4M$303.1M
ROE-72.8%13.9%-7.0%
Per Share
EPS$-3.54$0.93$-0.40
Cash Flow
Operating CF-$38.0M$42.0M

Source: XBRL data in CareDx, Inc. (CDNA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CDNA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CDNA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$1.47B
Q2 202631$595.0M
Q1 202630$351.2M
Q4 202528$390.4M
Q3 202528$301.5M
Q2 202529$464.9M
Q1 202527$361.9M
Q4 202423$398.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 226 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CDNA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 9, 2026--
4Nov 9, 2026--
4Nov 4, 2026--
4Nov 3, 2026--
10-QOct 29, 2026Analysis
8-KOct 29, 2026Analysis-
4Oct 5, 2026--
4Oct 5, 2026--
4Oct 5, 2026--
4Oct 5, 2026--
4Oct 5, 2026--
8-KSep 16, 2026Analysis-
4Sep 15, 2026--
4Sep 15, 2026--
SC 13GAug 7, 2026-
4Aug 6, 2026--
4Aug 6, 2026--
4Aug 6, 2026--
4Aug 6, 2026--
4Aug 4, 2026--

Related Health Care companies

All Health Care →

CDNA SEC filings: frequently asked questions

Are CDNA insiders buying or selling?

In the last 90 days, CareDx, Inc. (CDNA) officers, directors and 10% owners reported no open-market purchases and 20 open-market sales worth $6.8 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CDNA stock?

As of September 30, 2026, the largest CareDx, Inc. (CDNA) holders among the 13F filers tracked by SignalX were BlackRock ($316.7 million), State Street Corp ($170.5 million), Vanguard Capital Management LLC ($142.6 million), ARK Investment Management ($104.6 million), Franklin Resources ($84.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CDNA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CareDx, Inc. (CDNA) reported revenue of $379.8 million (up 13.8% from FY2024) and a net loss of $21.4 million. Diluted EPS was -$0.40. The figures come from the XBRL data in the 10-K.

What are the main risks in CDNA's latest 10-K?

In the 10-K filed February 25, 2026, CareDx, Inc. (CDNA) flagged: MolDX/Noridian Proposed LCD revision may reduce reimbursement, impose utilization limits, and introduces bundled payment, with final decision due within 365 days from July 17, 2025. Medicare reimbursement risk: 46% of testing revenue from Medicare, with AlloSure Kidney 2026 fee reduced by $88 to $2,753 per test after CMS crosswalk decision. (AI summary of the Risk Factors section.)

What did CDNA report in its latest 8-K?

CareDx, Inc. (CDNA) filed an 8-K on October 29, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Updated corporate presentation current as of September 30, 2026.

What are the latest CDNA SEC filings?

CareDx, Inc. (CDNA) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 18, 2026.

What is CDNA's SEC CIK number?

CareDx, Inc. (CDNA)'s SEC Central Index Key (CIK) is 1217234. EDGAR lists every CDNA filing under that number.

Ask anything about CDNA

The research agent reads CDNA's filings, financials, insider trades and 13F holders, then answers with sources.